Newsbenzinga
FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints
· Published
Article summary
Rezolute (NASDAQ: RZLT) shares surged after the FDA recommended a pre-BLA meeting for its congenital hyperinsulinism drug, ersodetug.
An excerpt from the original article.
Comments —
Loading comments…